Stellar Biotechnologies, Inc. is a biotechnology company. The Company is engaged in the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH). KLH is an immune-stimulating protein. KLH can be used as an active pharmaceutical ingredient (API) and combined with a disease-targeting agent to create immunotherapies for the treatment of a range of diseases. The Company's core business is developing and commercializing Keyhole Limpet Hemocyanin for use in immunotherapy and immunodiagnostic applications. The Company's Stellar KLH product offerings include Stellar KLH protein for conjugation and as carrier molecule in immunotherapy development; Stellar KLH protein and enzyme-linked immunosorbent assay (ELISA) test kits for immune function testing, and Custom KLH formulations, adjuvants, conjugations and fill finishes for preclinical research and drug development applications.
Industry, Sector and Symbol:
- Market Cap: $12.67 million
- Outstanding Shares: 10,136,000
- 50 Day Moving Avg: $1.34
- 200 Day Moving Avg: $1.75
- 52 Week Range: $1.19 - $5.68
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.29
- P/E Growth: 0.00
- Annual Revenue: $662,069.00
- Price / Sales: 19.14
- Book Value: $0.97 per share
- Price / Book: 1.29
- EBIDTA: ($4,900,000.00)
- Net Margins: -528.08%
- Return on Equity: -49.34%
- Return on Assets: -46.23%
- Current Ratio: 17.63%
- Quick Ratio: 17.10%
- Average Volume: 86,514 shs.
- Beta: 0.55
- Short Ratio: 0.17
Frequently Asked Questions for Stellar Biotechnologies (NASDAQ:SBOT)
What is Stellar Biotechnologies' stock symbol?
Stellar Biotechnologies trades on the NASDAQ under the ticker symbol "SBOT."
How were Stellar Biotechnologies' earnings last quarter?
Stellar Biotechnologies Inc (NASDAQ:SBOT) issued its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.15) by $0.04. The company had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.33 million. Stellar Biotechnologies had a negative net margin of 528.08% and a negative return on equity of 49.34%. View Stellar Biotechnologies' Earnings History.
Where is Stellar Biotechnologies' stock going? Where will Stellar Biotechnologies' stock price be in 2017?
1 equities research analysts have issued twelve-month price objectives for Stellar Biotechnologies' shares. Their forecasts range from $4.00 to $4.00. On average, they expect Stellar Biotechnologies' share price to reach $4.00 in the next twelve months. View Analyst Ratings for Stellar Biotechnologies.
Who are some of Stellar Biotechnologies' key competitors?
Some companies that are related to Stellar Biotechnologies include Cytori Therapeutics (CYTX), Heat Biologics (HTBX), Eleven Biotherapeutics (EBIO), Streamline Health Solutions (STRM), Auris Medical Holding AG (EARS), OHR Pharmaceutical (OHRP), CareDx (CDNA), Proteon Therapeutics (PRTO), Galena Biopharma (GALE), TrovaGene (TROV), Eyegate Pharmaceuticals (EYEG), OncoSec Medical (ONCS), Rewalk Robotics Ltd (RWLK), Aviragen Therapeutics (AVIR), Aptose Biosciences (APTO), Aradigm (ARDM), CorMedix (CRMD) and Alliqua Biomedical (ALQA).
How do I buy Stellar Biotechnologies stock?
Shares of Stellar Biotechnologies can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Stellar Biotechnologies stock cost?
One share of Stellar Biotechnologies stock can currently be purchased for approximately $1.25.
Consensus Ratings for Stellar Biotechnologies (NASDAQ:SBOT) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||1 Buy Rating|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$4.00 (220.00% upside)|
Analysts' Ratings History for Stellar Biotechnologies (NASDAQ:SBOT)
(Data available from 5/25/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|12/2/2016||Maxim Group||Lower Price Target||Buy||$7.00 -> $4.00||N/A|
Earnings History for Stellar Biotechnologies (NASDAQ:SBOT)Earnings History by Quarter for Stellar Biotechnologies (NASDAQ:SBOT)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/9/2017||Q2 2017||($0.15)||($0.11)||$0.33 million||$0.06 million||View||N/A|
|2/6/2017||Q1 2017||($0.10)||($0.15)||$0.31 million||$0.14 million||View||N/A|
Earnings Estimates for Stellar Biotechnologies (NASDAQ:SBOT)
2017 EPS Consensus Estimate: ($0.60)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Stellar Biotechnologies (NASDAQ:SBOT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Stellar Biotechnologies (NASDAQ:SBOT)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Stellar Biotechnologies (NASDAQ:SBOT)
Latest Headlines for Stellar Biotechnologies (NASDAQ:SBOT)
|Stellar Biotechnologies Inc (SBOT) Posts Earnings Results, Beats Estimates By $0.04 EPS|
www.americanbankingnews.com - May 10 at 6:40 PM
|Stellar Biotechnologies Reports Second Quarter 2017 Financial Results - PR Newswire (press release)|
www.prnewswire.com - May 10 at 11:02 AM
|Stellar Biotechnologies (SBOT) Earns Daily News Sentiment Rating of 0.08|
www.americanbankingnews.com - May 1 at 5:36 PM
|Stellar Biotechnologies (SBOT) Earning Positive Media Coverage, AlphaOne Reports|
www.americanbankingnews.com - April 28 at 6:50 PM
|Stellar Biotechnologies (SBOT) Receives Daily News Impact Rating of 0.33|
www.americanbankingnews.com - April 22 at 12:55 PM
|STELLAR BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to|
biz.yahoo.com - March 29 at 8:32 AM
|Stellar Biotechnologies (SBOT) to Sell 'Immunogen & Vaccine Technology' to Matrivax|
www.streetinsider.com - March 13 at 7:24 PM
|Stellar Biotechnologies and Matrivax Sign Agreement to Transfer Vaccine Technology|
us.rd.yahoo.com - March 13 at 7:24 PM
|STELLAR BIOTECHNOLOGIES, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Other Events, Finan|
biz.yahoo.com - March 13 at 7:24 PM
|The Life Sciences Report Examines Stellar Biotechnologies (SBOT:NASDAQ) Inking Multiyear KLH Supply Agreement with Amaran Biotechnology; Stellar Up 27% on News|
finance.yahoo.com - March 6 at 11:51 AM
|Amaran Biotechnology Selects Stellar KLH for Cancer Vaccines - Yahoo Finance|
finance.yahoo.com - March 4 at 12:44 AM
|Amaran Biotechnology Selects Stellar KLH for Cancer Vaccines - PR Newswire (press release)|
www.prnewswire.com - March 2 at 1:02 AM
|Amaran Biotechnology Selects Stellar KLH for Cancer Vaccines|
us.rd.yahoo.com - March 1 at 10:06 AM
|SBOT: Q1 Light On Revenue But Clinical Trial Progression Suggests Growth Ahead|
finance.yahoo.com - February 10 at 2:12 AM
|Stellar Biotechnologies Reports First Quarter 2017 Financial Results - PR Newswire (press release)|
www.prnewswire.com - February 7 at 8:08 AM
|8:24 am Stellar Biotechnologies issues a statement congratulating Neovacs S.A. for its decision to extend the development of its lupus drug for Type 1 diabetes|
us.rd.yahoo.com - February 7 at 12:53 AM
|Stellar Biotechnologies Reports First Quarter 2017 Financial Results|
finance.yahoo.com - February 6 at 7:49 PM
|Stellar Biotechnologies Congratulates Partner's Decision to Extend Drug Development for Diabetes|
finance.yahoo.com - February 6 at 8:34 AM
|7:31 am Stellar Biotechnologies to expand production of its Stellar KLH products under a recently established Mexican subsidiary|
finance.yahoo.com - January 11 at 10:27 PM
|Stellar Biotechnologies to Present at Biotech Showcase Conference|
finance.yahoo.com - January 5 at 6:29 AM
|SBOT: 2016 A Solid Year, Both Financially and Operationally|
finance.yahoo.com - December 20 at 2:33 PM
|STELLAR BIOTECHNOLOGIES, INC. Financials|
finance.yahoo.com - December 20 at 2:33 PM
|Stellar Biotechnologies Reports Fiscal Year 2016 Financial Results|
finance.yahoo.com - December 14 at 10:01 PM
|STELLAR BIOTECHNOLOGIES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements|
biz.yahoo.com - December 14 at 10:01 PM
|Stellar Biotechnologies Announces Fiscal Year 2016 Corporate Update Conference Call|
finance.yahoo.com - December 12 at 9:17 AM
|STELLAR BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial|
biz.yahoo.com - December 9 at 7:36 PM
Stellar Biotechnologies (SBOT) Chart for Thursday, May, 25, 2017